Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued Access to BXQ-350 (ETERNITI)
NCT04404569Phase 1Terminated
- Sponsor
- Bexion Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BXQ-350 in Neoplasm, sponsored by Bexion Pharmaceuticals. Primary endpoint: Percentage of subjects with clinical benefit at 5 years. Started Jun 2020; status: terminated.
02
Drugs
BXQ-350
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT04404569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404569.